BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) rose 5% during trading on Monday . The stock traded as high as $2.59 and last traded at $2.52, with a volume of 206,837 shares trading hands. The stock had previously closed at $2.40.

Separately, Maxim Group reaffirmed a “buy” rating and issued a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a research report on Wednesday, May 11th.

The firm’s market cap is $45.70 million. The stock’s 50 day moving average is $2.50 and its 200 day moving average is $2.40.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings results on Tuesday, May 10th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.25) by $0.15. Equities research analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.58) earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.